Abstract
Rationale
The serotonergic system has been implicated in emotional processing in animals and humans. Although the contribution of different receptor subtypes has been hypothesised, there have been few direct tests of this in human subjects.
Objectives
The current study aimed to explore the involvement of the serotonin type 3 (5HT3) receptor subtype in a battery of emotional processing tasks previously found to be sensitive to SSRI administration.
Materials and methods
Healthy volunteers were randomised to receive the 5HT3 antagonist, ondansetron (12 mg, oral), or placebo in a double blind between groups design. Emotional processing was assessed using three tasks: affective modulation of the startle reflex, emotional categorisation and memory and facial expression recognition. Subjective state ratings, blood pressure and pulse were also collected before and after ondansetron and placebo.
Results
Ondansetron was well tolerated and did not affect subjective measures of mood, anxiety or well-being in these healthy volunteers. However, the emotion potentiated effect was abolished in the volunteers receiving ondansetron. Facial expression recognition and emotional memory were not significantly affected.
Conclusions
These results suggest an involvement of 5HT3 receptors in certain aspects of fear processing in humans. These effects are consistent with anxiolytic actions of 5HT3 antagonism in animal models and suggest that the 5HT3 receptor may play a role in the effects of serotonergic manipulations on fear and anxiety.
Similar content being viewed by others
References
Anderson NH (1968) Likableness ratings of 555 personality trait words. J Pers Soc Psychol 9:272–279
Attenburrow MJ, Williams C, Odontiadis J, Reed A, Powell J, Cowen PJ, Harmer CJ (2003) Acute administration of nutritionally sourced tryptophan increases fear recognition. Psychopharmacology (Berl) 169:104–107
Baas JM, Grillon C, Bocker KB, Brack AA, Morgan CA, III, Kenemans JL, Verbaten MN (2002) Benzodiazepines have no effect on fear-potentiated startle in humans. Psychopharmacology (Berl) 161:233–247
Bhagwagar Z, Cowen PJ, Goodwin GM, Harmer CJ (2004a) Normalization of enhanced fear recognition by acute SSRI treatment in subjects with a previous history of depression. Am J Psychiatry 161:166–168
Bhagwagar Z, Rabiner EA, Sargent PA, Grasby PM, Cowen PJ (2004b) Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635. Mol Psychiatry 9:386–392
Burghardt NS, Sullivan GM, McEwen BS, Gorman JM, LeDoux JE (2004) The selective serotonin reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: a comparison with tianeptine. Biol Psychiatry 55:1171–1178
Calder AJ, Lawrence AD, Young AW (2001) Neuropsychology of fear and loathing. Nat Rev Neurosci 2:352–363
Davis M (1993) Pharmacological analysis of fear-potentiated startle. Braz J Med Biol Res 26:235–260
Drevets WC, Frank E, Price JC, Kupfer DJ, Holt D, Greer PJ, Huang Y, Gautier C, Mathis C (1999) PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry 46:1375–1387
Ekman P, Friesen WV (1976) Pictures of facial affect. Consulting Psychologists, Palo Alto, California
Graeff FG (2002) On serotonin and experimental anxiety. Psychopharmacology (Berl) 163:467–476
Grillon C (2002) Startle reactivity and anxiety disorders: aversive conditioning, context, and neurobiology. Biol Psychiatry 52:958–975
Grillon C, Baas J (2003) A review of the modulation of the startle reflex by affective states and its application in psychiatry. Clin Neurophysiol 114(9):1557–1579
Harmer CJ, Bhagwagar Z, Perrett DI, Vollm BA, Cowen PJ, Goodwin GM (2003) Acute SSRI administration affects the processing of social cues in Healthy Volunteers. Neuropsychopharmacology 28:148–152
Harmer CJ, Shelley NC, Cowen PJ, Goodwin GM (2004) Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Am J Psychiatry 161:1256–1263
Hayward G, Goodwin GM, Cowen PJ, Harmer CJ (2005) Low-dose tryptophan depletion in recovered depressed patients induces changes in cognitive processing without depressive symptoms. Biol Psychiatry 57:517–524
Jackson MB, Yakel JL (1995) The 5-HT3 receptor channel. Annu Rev Physiol 57:447–468
Kent JM, Coplan JD, Gorman JM (1998) Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety. Biol Psychiatry 44:812–824
Killcross S, Robbins TW, Everitt BJ (1997) Different types of fear-conditioned behaviour mediated by separate nuclei within amygdala. Nature 388:377–380
Lang PJ, Davis M, Ohman A (2000) Fear and anxiety: animal models and human cognitive psychophysiology. J Affect Disord 61:137–159
Larson CL, Ruffalo D, Nietert JY, Davidson RJ (2000) Temporal stability of the emotion-modulated startle response. Psychophysiology 37:92–101
LeDoux JE (2000) Emotion circuits in the brain. Annu Rev Neurosci 23:155–184
Morales M, Bloom FE (1997) The 5-HT3 receptor is present in different subpopulations of GABAergic neurons in the rat telencephalon. J Neurosci 17:3157–3316
Murphy SE, Longhitano C Goodwin GM, Cowen PJ, Harmer CJ (2005) Does tryptophan supplementation induce similar changes in emotional processing to an SSRI? J Psychopharmacol, (abstract): SV19
Nevins ME, Anthony EW (1994) Antagonists at the serotonin-3 receptor can reduce the fear-potentiated startle response in the rat: evidence for different types of anxiolytic activity? J Pharmacol Exp Ther 268:248–254
Olivier B, van W, I, Soudijn W (2000) 5-HT(3) receptor antagonists and anxiety; a preclinical and clinical review. Eur Neuropsychopharmacol 0:77–95
Spielberger CD, Gorsuch RL, Luschene RE (1970) Manual for the State-Trait Inventory. Consulting Psychologists, Palo Alto, California
Young AW, Rowland D, Calder AJ, Etcoff NL, Seth A, Perrett DI (1997) Facial expression megamix: tests of dimensional and category accounts of emotion recognition. Cognition 63:271–313
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Harmer, C.J., Reid, C.B., Ray, M.K. et al. 5HT3 antagonism abolishes the emotion potentiated startle effect in humans. Psychopharmacology 186, 18–24 (2006). https://doi.org/10.1007/s00213-006-0337-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-006-0337-z